The results of the Intergroup 00-99 trial represented a key turning point for the management of nasopharyngeal cancer and heralded a new era of concurrent chemoradiation regimens. These findings were built on by the addition of intensity-modulated radiotherapy to tackle local failure. As a result, 90% local control rates for nasopharyngeal cancer can be expected, leaving the battle for distant control as the most pressing research problem.